Repligen | RGEN - Actif À Court Terme





Actif À Court Terme Changement Date
Agilent USD 4.69B 70M 2026-06
Align Technology USD 2.73B 63.03M 2026-09
Bio Techne USD 824.83M 80.43M 2026-09
BioMarin Pharmaceutical USD 3.92B 50.99M 2026-09
Bristol-Myers Squibb USD 29.77B 1.19B 2026-09
Bruker USD 2.16B 67.9M 2026-09
Charles River Laboratories USD 1.54B 5.92M 2026-09
Danaher USD 14.79B 1.41B 2026-09
Dentsply International USD 1.98B 50M 2026-09
General Electric Aerospace USD 41.53B 1.83B 2026-09
Henry Schein USD 4.78B 176M 2026-09
Illumina USD 3.04B 201M 2026-09
IQVIA Holdings USD 6.45B 225M 2026-09
Mettler Toledo International USD 1.38B 28.79M 2026-09
Myriad Genetics USD 289M 23.8M 2026-06
OraSure Technologies USD 222.94M 17.84M 2026-06
Pacific Biosciences Of California USD 307.85M 30.78M 2026-09
Pfizer USD 45.01B 3.65B 2026-09
Repligen USD 1.24B 41.43M 2026-09
Revvity USD 1.86B 436.33M 2026-09
Standard Biotools USD 497.3M 19.56M 2026-09
Thermo Fisher Scientific USD 25.62B 2.25B 2026-09
Waters USD 3.9B 186M 2026-06
West Pharmaceutical Services USD 1.82B 9M 2026-09